NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.

Prochazka, KT; Melchardt, T; Posch, F; Schlick, K; Deutsch, A; Beham-Schmid, C; Weiss, L; Gary, T; Neureiter, D; Klieser, E; Greil, R; Neumeister, P; Egle, A; Pichler, M; Br J Cancer. 2016; 115(10):1264-1272

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.

Karthaus, M; Hofheinz, RD; Mineur, L; Letocha, H; Greil, R; Thaler, J; Fernebro, E; Oliner, KS; Boedigheimer, M; Twomey, B; Zhang, Y; Demonty, G; Köhne, CH; Br J Cancer. 2016; 115(10):1215-1222

Denosumab in the Treatment of Breast Cancer Patients with Bone Metastasis

Steger, G; Bartsch, R; Fridrik, MA; Gampenrieder, SP; Marth, C BREAST CARE. 2016; 11(5): 363-365.

A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study

Leierer, G; Grabmeier-Pfistershammer, K; Steuer, A; Sarcletti, M; Geit, M; Haas, B; Taylor, N; Kanatschnig, M; Rappold, M; Ledergerber, B; Zangerle, R OPEN FORUM INFECT DI. 2016; 3(2):

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.

Zelle-Rieser, C; Thangavadivel, S; Biedermann, R; Brunner, A; Stoitzner, P; Willenbacher, E; Greil, R; Jöhrer, K; J Hematol Oncol. 2016; 9(1):116

Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.

Magnes, T; Melchardt, T; Weiss, L; Hufnagl, C; Greil, R; Egle, A; J Clin Oncol. 2016; 34(20):2433-2434

Bcl-2 proteins in development, health, and disease of the hematopoietic system.

Kollek, M; Müller, A; Egle, A; Erlacher, M; FEBS J. 2016; 283(15): 2779-2810.

Diagnostic challenges in vacuolar myelopathy: a didactic case report.

Ernst, F; Klausner, F; Kleindienst, W; Bartsch, H; Taylor, N; Trinka, E; Spinal Cord Ser Cases. 2016; 2: 16020

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)

Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R CANCER RES. 2017; 77:

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)

Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Greil, R; Rudas, M; Tea, MK; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Michael, G CANCER RES. 2017; 77: